65,437 trials
Diabetes Mellitus, Type 2
Primary: Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy — 1.44; 1.72; 1.41; 3.77 hours
Colorectal Carcinoma
Primary: Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period — 1 participants
Nonsquamous Non-Small Cell Neoplasm of Lung · Non-Small Cell Lung Cancer Metastatic · Non-Small Cell Lung Cancer Stage IIIB
Primary: Percentage of Participants Who Adhered to Treatment Administration at Home — 100; 98.0; 98.0; 98.0 percentage of participants
Opiate Dependence
Primary: Illicit Opioid Abstinence — 10.29; 10.12 Weeks of Abstinence — p=.91
Adult Anaplastic Oligodendroglioma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: 6-month Progression-free Survival (PFS), Defined as a Patient Being Alive and Progression-free 183 Days After the Date of Registration. — 33.35; 33.3; 25 percentage of…
Hearing Impairment
Primary: Psychosocial Impact of Assistive Devices Scale (PIADS) — 1.06; 0.85 units on a scale — p=>0.05
Hereditary Angioedema (HAE)
Primary: Occurrence of Anaphylaxis or Other Adverse Events Suggestive of Hypersensitivity — 4; 2 participants
HER2 Positive Breast Carcinoma · Recurrent Breast Carcinoma · Stage IIIB Breast Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.0; 4.9 Median survival and CI in months — p=.89
Psoriasis
Primary: Mean Percent Change From Baseline in the Psoriasis and Activity Severity Index (PASI) Score at Day 29 — -3.30; -2.14 Score on a Scale
Pneumonia, Pneumococcal · Pneumococcal Infections · 13-valent Pneumococcal Vaccine
Primary: Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP) — 49; 90 participants — p=0.0006
Alveolitis, Fibrosing · Fibrosis, Pulmonary · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Test — -26; -7 meters
Meningococcal Disease · Infections, Meningococcal
Primary: Non-inferiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N…
Lung Cancer · Non-Small-Cell Lung Carcinoma
Primary: Determine Objective Response Rate — 0; 5; 14; 9 patients
Cobalt Biokinetics · Safety of Cobalt Dietary Supplementation
Primary: Cobalt Whole Blood Concentrations — 14.6; 7.4; 33.9; 8.5 µg Co/L
Cystic Fibrosis · Anemia, Iron-Deficiency
Primary: Change From Baseline in Hemoglobin Concentration (gm/dl) — 0.12; 0.09 gm/dl — p=0.81